- Home
- PRG vs RCKT Comparison
PRG vs RCKT Comparison
Compare PRG & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRG | RCKT |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 534.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRG | RCKT |
|---|---|---|
| Price | $28.61 | $3.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $47.50 | $29.73 |
| AVG Volume (30 Days) | 478.0K | ★ 4.2M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.59 | N/A |
| Revenue | ★ $2,409,223,000.00 | N/A |
| Revenue This Year | $24.02 | N/A |
| Revenue Next Year | $7.06 | $51.17 |
| P/E Ratio | $7.85 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.53 | $2.19 |
| 52 Week High | $41.14 | $8.26 |
Technical Indicators
Market Signals| Indicator | PRG | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 37.22 |
| Support Level | $27.47 | $3.43 |
| Resistance Level | $30.40 | $3.52 |
| Average True Range (ATR) | 0.92 | 0.37 |
| MACD | 0.14 | -0.15 |
| Stochastic Oscillator | 55.08 | 3.12 |
Price Performance
Historical ComparisonAbout PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.